von Tresckow, J., Cramer, P., Robrecht, S., Langerbeins, P., Fink, A., Al-Sawaf, O., . . . Hallek, M. (2022). Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL). Leukemia, 36(8), 2125. https://doi.org/10.1038/s41375-022-01629-7
Chicago-referens (17:e uppl.)von Tresckow, Julia, et al. "Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL)." Leukemia 36, no. 8 (2022): 2125. https://doi.org/10.1038/s41375-022-01629-7.
MLA-referens (9:e uppl.)von Tresckow, Julia, et al. "Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL)." Leukemia, vol. 36, no. 8, 2022, p. 2125, https://doi.org/10.1038/s41375-022-01629-7.
